Cancers, Volume 16, Issue 21
2024 November-1 - 165 articles
Cover Story: Improving knowledge in AML immunobiology may translate to better clinical developments in immunotherapies for patients with AML. Harnessing the immune system against leukemia cells can be a powerful treatment strategy for AML patients. Immune-based therapies such as BiTE and CAR-T cell therapy have proven to be effective means of targeting chemotherapy resistance in AML, but their therapeutic benefits are not durable and limited only to a fraction of patients. However, despite these limitations, recent studies have shown the peculiar sensitivity of some AML subtypes to immunotherapy, such as multiplex antigen targeting, and have provided the basis for future studies, thus holding the promise of successful clinical developments. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.